Supplementary Information

*Brief Research Report*

**Assessment of molecular residual disease using circulating tumor DNA to identify multiple myeloma patients at high risk of relapse**

Binod Dhakal1, Shruti Sharma2, Mustafa Balcioglu2, Svetlana Shchegrova2, Meenakshi Malhotra2, Bernhard Zimmermann2, Paul R. Billings2, Alexandra Harrington3,Himanshu Sethi2, Alexey Aleshin2 and Parameswaran Hari1

1.Division of BMT & Cellular Therapy, Medical College of Wisconsin, Milwaukee, WI

2. Natera, Inc., Austin, TX

3. Department of Pathology, Medical College of Wisconsin, Milwaukee, WI

**Key words:** circulating tumor DNA **(**ctDNA), tumor-informed, minimal residual disease (MRD), multiple myeloma (MM), multiparameter flow cytometry (MFC)

**Short title:** ctDNA in multiple myeloma

**Corresponding author:**

Parameswaran Hari, MD, MRCP

Chief Professor of Medicine

Medical College of Wisconsin

Milwaukee, WI

Email: phari@mcw.edu



**Supplementary Figure 1.** MFC histograms showing residual disease from a patient. Residual myeloma cells (red) are CD38 (bright+), positive for CD20, CD117, CD200, and lambda light chain and negative for CD19 and CD56. Red: myeloma cells; magenta: hematogones; blue: B cells.